[
    [
        {
            "time": "",
            "original_text": "交银国际：白云山维持中性评级 目标价升至23.30港元",
            "features": {
                "keywords": [
                    "交银国际",
                    "白云山",
                    "中性评级",
                    "目标价",
                    "23.30港元"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "交银国际：白云山维持中性评级 目标价升至23.30港元",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【券商聚焦】交银微升白云山(00874)目标价3.6%至23.3港元 维持“中性”评级",
            "features": {
                "keywords": [
                    "券商",
                    "交银",
                    "白云山",
                    "目标价",
                    "3.6%",
                    "23.3港元",
                    "中性评级"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【券商聚焦】交银微升白云山(00874)目标价3.6%至23.3港元 维持“中性”评级",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "广药白云山上半年现金流大增",
            "features": {
                "keywords": [
                    "广药",
                    "白云山",
                    "上半年",
                    "现金流",
                    "大增"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "广药白云山上半年现金流大增",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]